Tafasitamab Plus Lenalidomide Shows Manageable Safety Profile in R/R DLBCL

Gilles Salles, MD, the lymphoma service chief at Memorial Sloan Kettering Cancer Center discusses the safety profile of tafasitamab combined with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma, based on results of the L-MIND trial.

Gilles Salles, MD, the lymphoma service chief at Memorial Sloan Kettering Cancer Center discusses the safety profile of tafasitamab (Monjuvi) combined with lenalidomide (Revlimid) for the treatment of relapsed or refractory diffuse large B-cell lymphoma, based on results of the L-MIND trial.

According to Salles, 50% of patients experienced a drop in white blood cell count and 1/3 of patients required an injection to boost count. Additionally, 1 in 6 patients experienced infection that may led to hospitalization. Most of these infections were common, however some lead to hospitalization. No instances of septic shock were reported. 

Anemia occurred in 1/3 of patients. Patients also experienced platelet cell diminishment. One in 6 patients required treatment for these adverse events.